MHYO-LCL1 Pre-leukaemic (DNMT3a R882H mutant) Human B-lymphoblast Cell Line
Invented by MIchal Hayun at Rambam Health Care Campus
Catalogue Number | 160592 |
Antigen/Gene or Protein Targets | Leukaemia |
Parental Line | Novel patient-derived (female; acute myeloid leukaemia) cell line |
Host | Human |
Tissue | Blood |
Disease Keywords | Leukaemia, Cancer |
Model | Tumour line |
Relevance |
The MHYO-LCL2 is an immortalised cancer cell line derived from a patient with acute myeloid leukaemia. The cell type is B-lymphoblast. This cell line is a useful tool for reactivation of EBV-specific cytotoxic T-lymphocytes in vitro. |
Production Details | This cell line was spontaneously grown from peripheral blood drawn from a female acute myeloid leukaemia patient upon diagnosis. This line was established in culture four weeks after seeding the AML blast cells. The cells contain low EBV mRNA expression and secret EBV into media, confirming immortalisation and transformation. These cells are in suspension and mostly grow as aggregates. |
Conditional | No |
Research Area | Cancer |
Growth/Phenotype Keywords | B-lymphoblast. Morphology: B-lymphoblastoid. Confirmed antigen expression: CD19, CD20, CD27, CD38, IgG. Confirmed cytokine secretion: IL-6, IL-10. |
Recommended Growing Conditions | Cells have been grown in IScove Modified Dulbecco's Medium containing 10% foetal bovine serum and 1% pencicillin/streptomycin. Cells are grown at 37 degrees celsius and 5% CO2. Cultures were split at confluency 1:2 or 1:3 two or three times per week. |
Notes |
Relevant research areas include: Drug discovery, B-cell biology, B-cell development and transformation, and acute myeloid leukaemia. These cells are polyclonal as confirmed by IGH gene clonality assay. |
There are 0 reference entries for this reagent.
|
Michal Hayun |